nach oben

Erschienen in:

29.01.2016 | Original Article

Comparison of parathyroid hormone and strontium ranelate in combination with whole-body vibration in a rat model of osteoporosis

verfasst von: D. B. Hoffmann, S. Sehmisch, A. M. Hofmann, C. Eimer, M. Komrakova, D. Saul, M. Wassmann, K. M. Stürmer, M. Tezval

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

We investigated the combinatorial effects of whole-body vertical vibration (WBVV) with the primarily osteoanabolic parathyroid hormone (PTH) and the mainly antiresorptive strontium ranelate (SR) in a rat model of osteoporosis. Ovariectomies were performed on 76 three-month-old Sprague–Dawley rats (OVX, n = 76; NON-OVX, n = 12). After 8 weeks, the ovariectomized rats were divided into 6 groups. One group (OVX + PTH) received daily injections of PTH (40 µg/kg body weight/day) for 6 weeks. Another group (OVX + SR) was fed SR-supplemented chow (600 mg/kg body weight/day). Three groups (OVX + VIB, OVX + PTH + VIB, and OVX + SR + VIB) were treated with WBVV twice a day at 70 Hz for 15 min. Two groups (OVX + PTH + VIB, OVX + SR + VIB) were treated additionally with PTH and SR, respectively. The rats were killed at 14 weeks post-ovariectomy. The lumbar vertebrae and femora were removed for biomechanical and morphological assessment. PTH produced statistically significant improvements in biomechanical and structural properties, including bone mineral density (BMD) and trabecular bone quality. In contrast, SR treatment exerted mild effects, with significant effects in cortical thickness only. SR produced no significant improvement in biomechanical properties. WBVV as a single or an adjunctive therapy produced no significant improvements. In conclusion, vibration therapy administered as a single or dual treatment had no significant impact on bones affected by osteoporosis. PTH considerably improved bone quality in osteoporosis cases and is superior to treatment with SR.

Osterkamp R (2005) Population developments in Germany until 2050. Chirurg 76:10–18CrossRefPubMed

Ellegaard M, Kringelbach T, Syberg S, Petersen S, Jensen JE, Bruel A, Jorgensen NR, Schwarz P (2013) The effect of PTH(1-34) on fracture healing during different loading conditions. J Bone Miner Res 28:2145–55

Li YF, Zhou CC, Li JH, Luo E, Zhu SS, Feng G, Hu J (2012) The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats. Osteoporos Int 23:1463–1474CrossRefPubMed

Tsuchie H, Miyakoshi N, Kasukawa Y, Aonuma H, Shimada Y (2013) Intermittent administration of human parathyroid hormone before osteosynthesis stimulates cancellous bone union in ovariectomized rats. Tohoku J Exp Med 229:19–28CrossRefPubMed

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefPubMed

Aspenberg P (2013) Annotation: parathyroid hormone and fracture healing. Acta Orthop 84:4–6CrossRefPubMedPubMedCentral

Fahrleitner-Pammer A, Langdahl BL, Marin F, Jakob F, Karras D, Barrett A, Ljunggren O, Walsh JB, Rajzbaum G, Barker C, Lems WF (2011) Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int 22:2709–2719CrossRefPubMed

Jakob F, Oertel H, Langdahl B, Ljunggren O, Barrett A, Karras D, Walsh JB, Fahrleitner-Pammer A, Rajzbaum G, Barker C, Lems WF, Marin F (2012) Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. Eur J Endocrinol 166:87–97CrossRefPubMedPubMedCentral

DVO (2014) Prophylaxe, Diagnostik und Therapie der Osteoporose bei Männern ab dem 60. Lebensjahr und bei postmenopausalen Frauen. http://www.dv-osteologie.org/uploads/Leitlinie%202014/DVO-Leitlinie%20Osteoporose%202014%20Kurzfassung%20und%20Langfassung%2018.%2009.%202014.pdf

10.

Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312–321CrossRefPubMed

11.

Vestergaard P (2014) New strategies for osteoporosis patients previously managed with strontium ranelate. Ther Adv Musculoskelet Dis 6:217–225CrossRefPubMedPubMedCentral

12.

Nardone V, D’Asta F, Brandi ML (2014) Pharmacological management of osteogenesis. Clinics (Sao Paulo) 69:438–446CrossRef

13.

Stepan JJ (2013) Strontium ranelate: in search for the mechanism of action. J Bone Miner Metab 31:606–612CrossRefPubMed

14.

Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468

15.

Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816–2822CrossRefPubMed

16.

EMA (2014) PRAC recommends suspending use of Protelos/Osseor (strontium ranelate). http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/01/WC500159375.pdf

17.

Frost HM (2000) The Utah paradigm of skeletal physiology: an overview of its insights for bone, cartilage and collagenous tissue organs. J Bone Miner Metab 18:305–316CrossRefPubMed

18.

Rubin C, Turner AS, Mallinckrodt C, Jerome C, McLeod K, Bain S (2002) Mechanical strain, induced noninvasively in the high-frequency domain, is anabolic to cancellous bone, but not cortical bone. Bone 30:445–452CrossRefPubMed

19.

Tezval M, Biblis M, Sehmisch S, Schmelz U, Kolios L, Rack T, Stuermer KM, Stuermer EK (2011) Improvement of femoral bone quality after low-magnitude, high-frequency mechanical stimulation in the ovariectomized rat as an osteopenia model. Calcif Tissue Int 88:33–40CrossRefPubMed

20.

Komrakova M, Sehmisch S, Tezval M, Ammon J, Lieberwirth P, Sauerhoff C, Trautmann L, Wicke M, Dullin C, Stuermer KM, Stuermer EK (2013) Identification of a vibration regime favorable for bone healing and muscle in estrogen-deficient rats. Calcif Tissue Int 92:509–520CrossRefPubMedPubMedCentral

21.

Sehmisch S, Galal R, Kolios L, Tezval M, Dullin C, Zimmer S, Stuermer KM, Stuermer EK (2009) Effects of low-magnitude, high-frequency mechanical stimulation in the rat osteopenia model. Osteoporos Int 20:1999–2008CrossRefPubMedPubMedCentral

22.

Habermann B, Kafchitsas K, Olender G, Augat P, Kurth A (2010) Strontium ranelate enhances callus strength more than PTH 1-34 in an osteoporotic rat model of fracture healing. Calcif Tissue Int 86:82–89CrossRefPubMed

23.

Li YF, Luo E, Feng G, Zhu SS, Li JH, Hu J (2010) Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats. Osteoporos Int 21:1889–1897CrossRefPubMed

24.

Liu CC, Kalu DN (1990) Human parathyroid hormone-(1-34) prevents bone loss and augments bone formation in sexually mature ovariectomized rats. J Bone Miner Res 5:973–982CrossRefPubMed

25.

Komrakova M, Stuermer EK, Werner C, Wicke M, Kolios L, Sehmisch S, Tezval M, Daub F, Martens T, Witzenhausen P, Dullin C, Stuermer KM (2010) Effect of human parathyroid hormone hPTH (1-34) applied at different regimes on fracture healing and muscle in ovariectomized and healthy rats. Bone 47:480–492CrossRefPubMed

26.

Stuermer EK, Komrakova M, Sehmisch S, Tezval M, Dullin C, Schaefer N, Hallecker J, Stuermer KM (2014) Whole body vibration during fracture healing intensifies the effects of estradiol and raloxifene in estrogen-deficient rats. Bone 64:187–194CrossRefPubMed

27.

Sehmisch S, Erren M, Rack T, Tezval M, Seidlova-Wuttke D, Richter J, Wuttke W, Stuermer KM, Stuermer EK (2009) Short-term effects of parathyroid hormone on rat lumbar vertebrae. Spine 34:2014–2021CrossRefPubMed

28.

Tezval M, Stuermer EK, Sehmisch S, Rack T, Stary A, Stebener M, Konietschke F, Stuermer KM (2010) Improvement of trochanteric bone quality in an osteoporosis model after short-term treatment with parathyroid hormone: a new mechanical test for trochanteric region of rat femur. Osteoporos Int 21:251–261CrossRefPubMed

29.

Sehmisch S, Erren M, Kolios L, Tezval M, Seidlova-Wuttke D, Wuttke W, Stuermer KM, Stuermer EK (2010) Effects of isoflavones equol and genistein on bone quality in a rat osteopenia model. Phytother Res 24:S168–S174CrossRefPubMed

30.

Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610CrossRefPubMed

31.

Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28:2–17CrossRefPubMedPubMedCentral

32.

Komrakova M, Stuermer EK, Tezval M, Stuermer KM, Dullin C, Schmelz U, Doell C, Durkaya-Burchhardt N, Fuerst B, Genotte T, Sehmisch S (2014) Evaluation of twelve vibration regimes applied to improve spine properties in ovariectomized rats. Bone Reports doi:10.1016/j.bonr.2014.12.001

33.

Sehmisch S, Komrakova M, Kottwitz L, Dullin C, Schmelz U, Stuermer KM, Tezval M (2015) Effects of urocortin on spine? Results from the rat osteopenia model. Osteologie 2:99–106

34.

Tezval M, Hansen S, Schmelz U, Komrakova M, Stuermer KM, Sehmisch S (2015) Effect of urocortin on strength and microarchitecture of osteopenic rat femur. J Bone Miner Metab 33:154-60

35.

Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57CrossRefPubMed

36.

Slatkovska L, Alibhai SM, Beyene J, Cheung AM (2010) Effect of whole-body vibration on BMD: a systematic review and meta-analysis. Osteoporos Int 21:1969–1980CrossRefPubMedPubMedCentral

37.

Brouwers JE, van Rietbergen B, Ito K, Huiskes R (2010) Effects of vibration treatment on tibial bone of ovariectomized rats analyzed by in vivo micro-CT. J Orthop Res 28:62–69PubMed

38.

van der Jagt OP, van der Linden JC, Waarsing JH, Verhaar JA, Weinans H (2012) Low-magnitude whole body vibration does not affect bone mass but does affect weight in ovariectomized rats. J Bone Miner Metab 30:40–46CrossRefPubMed

39.

Judex S, Lei X, Han D, Rubin C (2007) Low-magnitude mechanical signals that stimulate bone formation in the ovariectomized rat are dependent on the applied frequency but not on the strain magnitude. J Biomech 40:1333–1339CrossRefPubMed

40.

Lynch MA, Brodt MD, Stephens AL, Civitelli R, Silva MJ (2011) Low-magnitude whole-body vibration does not enhance the anabolic skeletal effects of intermittent PTH in adult mice. J Orthop Res 29:465–472CrossRefPubMed

41.

Altman AR, de Bakker CM, Tseng WJ, Chandra A, Qin L, Liu XS (2015) Enhanced individual trabecular repair and its mechanical implications in parathyroid hormone and alendronate treated rat tibial bone. J Biomech Eng 137 doi: 10.1115/1.4028823

42.

Ma YL, Zeng QQ, Porras LL, Harvey A, Moore TL, Shelbourn TL, Dalsky GP, Wronski TJ, Aguirre JI, Bryant HU, Sato M (2011) Teriparatide [rhPTH (1-34)], but not strontium ranelate, demonstrated bone anabolic efficacy in mature, osteopenic, ovariectomized rats. Endocrinology 152:1767–1778CrossRefPubMed

43.

Recker RR, Marin F, Ish-Shalom S, Moricke R, Hawkins F, Kapetanos G, de la Pena MP, Kekow J, Farrerons J, Sanz B, Oertel H, Stepan J (2009) Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 24:1358–1368CrossRefPubMed

44.

Bruel A, Vegger JB, Raffalt AC, Andersen JE, Thomsen JS (2013) PTH (1-34), but not strontium ranelate counteract loss of trabecular thickness and bone strength in disuse osteopenic rats. Bone 53:51–58CrossRefPubMed

45.

Hamdy NA (2009) Strontium ranelate improves bone microarchitecture in osteoporosis. Rheumatology (Oxford) 48:iv9–13

46.

Brun LR, Galich AM, Vega E, Salerni H, Maffei L, Premrou V, Costanzo PR, Sarli MA, Rey P, Larroude MS, Moggia MS, Brance ML, Sánchez A, Grupo Argentino de Estudio del Ranelato de Estroncio (GAERE) (2014) Strontium ranelate effect on bone mineral density is modified by previous bisphosphonate treatment. Springerplus 3:676CrossRefPubMedPubMedCentral

47.

Ferrari S (2010) Comparing and contrasting the effects of strontium ranelate and other osteoporosis drugs on microarchitecture. Osteoporos Int 21:S437–S442CrossRefPubMed

48.

Gallacher SJ, Dixon T (2010) Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review. Calcif Tissue Int 87:469–484CrossRefPubMed

Titel: Comparison of parathyroid hormone and strontium ranelate in combination with whole-body vibration in a rat model of osteoporosis
verfasst von: D. B. Hoffmann
S. Sehmisch
A. M. Hofmann
C. Eimer
M. Komrakova
D. Saul
M. Wassmann
K. M. Stürmer
M. Tezval
Publikationsdatum: 29.01.2016
Verlag: Springer Japan
Erschienen in: Journal of Bone and Mineral Metabolism / Ausgabe 1/2017
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-016-0736-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Comparison of parathyroid hormone and strontium ranelate in combination with whole-body vibration in a rat model of osteoporosis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

The role of serum total and free 25-hydroxyvitamin D and PTH values in defining vitamin D status at the end of winter: a representative survey

Characterization and comparison of osteoblasts derived from mouse embryonic stem cells and induced pluripotent stem cells

Erratum to: Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw

Bone mineral density of postmenopausal women with rheumatoid arthritis depends on disease duration regardless of treatment

Relationship between spinal osteoarthritis and vertebral fractures in men older than 50 years: data from the Camargo Cohort Study

Bone mineral density and its determinants in men with opioid dependence

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin